Resistant Cystoid Macular Edema Clinical Trial
| Verified date | July 2008 |
| Source | hahid Beheshti University of Medical Sciences |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Iran: Ethics Committee |
| Study type | Interventional |
Cystoid macular edema (CME) is one of the common causes of vision loss in patients with UveitiS .Triamcinolone has been effectively used in reducing CME and improving the vision. Also there are some documents which recommend Bevacizumab(avastin) could reduce macular edema. This study compare intravitreous injection of triamcinolone and avastin in patients with resistant uveitic cystoid macular edema.
| Status | Active, not recruiting |
| Enrollment | 40 |
| Est. completion date | September 2008 |
| Est. primary completion date | May 2008 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: - Uveitic CME - Uveitic CME refractory to routine treatment - Vision better than 5/200 and worse than 20/50 Exclusion Criteria: - Mono- Ocular patients - History of vitrectomy - Glaucoma or ocular hypertension - History of other retinal disease that can cause macular edema - Pregnancy - Significant media opacity - Vision better than 20/50 |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Iran, Islamic Republic of | Masoud Soheilian , MD | Tehran |
| Lead Sponsor | Collaborator |
|---|---|
| hahid Beheshti University of Medical Sciences |
Iran, Islamic Republic of,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Resorbed CME in OCT | every 3 month | No | |
| Primary | Resorbed CME in clinical examination | Every 3 month | No | |
| Secondary | need to retreatment | when ever needed | No |